Where the blockbuster weight loss drug market stands today — and what's coming next
1. LLY leads GLP-1 market, capturing 57% of prescriptions. 2. Insurance coverage for obesity drugs remains limited. 3. Novo Nordisk faces significant challenges, impacting investor sentiment. 4. Oral GLP-1 treatments may reshape market landscape. 5. New weight loss medications challenging existing market leaders.